Non-Alcoholic Steatohepatitis

Midwest CEPAC

ICER plans to assess the comparative clinical effectiveness and value of obeticholic acid (Intercept) for the treatment of non-alcoholic steatohepatitis (NASH). Obeticholic acid has received a breakthrough therapy designation from the FDA, with an anticipated decision expected in the first half of 2020.

Associated Meetings

TBA

The Midwest CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for NASH.


Key Dates

Associated Materials

10/08/2019 – 10/25/2019
Open Input Period

10/30/2019
Draft Scoping Document

10/30/2019 – 11/20/2019
Public Comments

10/30/2019
Stakeholder List

12/02/2019
Revised Scoping Document

01/15/2020
Research Protocol

02/05/2020
Model Analysis Plan

03/19/2020
Draft Evidence Report

03/19/2020
Draft Voting Questions

03/19/2020 – 04/15/2020
Public Comments

05/07/2020
Revised Voting Questions

05/07/2020
Evidence Report

05/07/2020
Response to Comments

05/21/2020
Meeting Agenda

05/21/2020
Evidence Presentation

06/11/2020
Final Evidence Report and Meeting Summary

06/11/2020
Report-at-a-Glance